Somatic Mutations in VHL Germline Deletion Kindred Correlate with Mild Phenotype

Annals of Neurology

Volumn 55, Issue 2, 2004, Pages 236-240

  Wait, Scott D ^a   Vortmeyer, Alexander O ^a   Lonser, Russell R ^a   Chang, David T ^a   Finn, Michael A ^a   Bhowmick, Deb A ^a   Pack, Svetlana D ^a   Oldfield, Edward H ^a   Zhuang, Zhengping ^a  

^a NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; ALLELE; ARTICLE; CANCER PATIENT; CARCINOGENESIS; CENTRAL NERVOUS SYSTEM; CHROMOSOME 3P; CLINICAL ARTICLE; CLINICAL GENETICS; CONTROLLED STUDY; FEMALE; GENE; GERM LINE; HEMANGIOBLASTOMA; HETEROZYGOSITY LOSS; HUMAN; HUMAN TISSUE; MALE; MOLECULAR GENETICS; PHENOTYPE; POINT MUTATION; PRIORITY JOURNAL; SOMATIC MUTATION; TUMOR SUPPRESSOR GENE; VHL GENE; VON HIPPEL LINDAU DISEASE; WILD TYPE;

ADULT; CEREBELLAR NEOPLASMS; FEMALE; GENES, TUMOR SUPPRESSOR; GERM-LINE MUTATION; HEMANGIOBLASTOMA; HIPPEL-LINDAU DISEASE; HUMANS; IN SITU HYBRIDIZATION, FLUORESCENCE; LOSS OF HETEROZYGOSITY; MALE; MIDDLE AGED; PEDIGREE; PHENOTYPE; POINT MUTATION; POLYMERASE CHAIN REACTION; POLYMORPHISM, SINGLE-STRANDED CONFORMATIONAL; SEQUENCE DELETION;

EID: 0842347575     PISSN: 03645134     EISSN: None     Source Type: Journal    
DOI: 10.1002/ana.10807     Document Type: Article

References (33)

1. Latif F, Tory K, Gnarra J, et al. Identification of the von Hippel-Lindau disease tumor suppressor gene. Science 1993;260:1317-1320.
2. Seizinger BR, Rouleau GA, Ozelius LJ, et al. Von Hippel-Lindau disease maps to the region of chromosome 3 associated with renal cell carcinoma. Nature 1988;332:268-269.
3. Choyke PL, Glenn GM, Walther MM, et al. von Hippel-Lindau disease: genetic, clinical, and imaging features. Radiology 1995;194:629-642.
4. Kaelin WG Jr. Molecular basis of the VHL hereditary cancer syndrome. Nat Rev Cancer 2002;2:673-682.
5. Maher ER, Kaelin WG Jr. von Hippel-Lindau disease. Medicine (Balt) 1997;76:381-391.
6. Manski TJ, Heffner DK, Glenn GM, et al. Endolymphatic sac tumors. A source of morbid hearing loss in von Hippel-Lindau disease. JAMA 1997;277:1461-1466.
7. Lonser RR, Glenn G, Chew EW, et al. von Hippel-Lindau disease. Lancet 2003;361:2059-67.
8. Knudson AG. Hereditary cancer, oncogenes, and antioncogenes. Cancer Res 1985;45:1437-1443.
9. Lee JY, Dong SM, Park WS, et al. Loss of heterozygosity and somatic mutations of the VHL tumor suppressor gene in sporadic cerebellar hemangioblastomas. Cancer Res 1998;58:504-508.
10. Lott ST, Chandler DS, Curley SA, et al. High frequency loss of heterozygosity in von Hippel-Lindau (VHL)-associated and sporadic pancreatic islet cell tumors: evidence for a stepwise mechanism for malignant conversion in VHL tumorigenesis. Cancer Res 2002;62:1952-1955.
11. Stolle C, Glenn G, Zbar B, et al. Improved detection of germline mutations in the von Hippel-Lindau disease tumor suppressor gene. Hum Mutat 1998;12:417-423.
12. Richards FM, Phipps ME, Latif F, et al. Mapping the Von Hippel-Lindau disease tumour suppressor gene: identification of germline deletions by pulsed field gel electrophoresis. Hum Mol Genet 1993;2:879-882.
13. Yao M, Latif F, Orcutt ML, et al. von Hippel-Lindau disease: identification of deletion mutations by pulsed-field gel electrophoresis. Hum Genet 1993;92:605-614.
14. Cybulski C, Krzystolik K, Murgia A, et al. Germline mutations in the von Hippel-Lindau (VHL) gene in patients from Poland: disease presentation in patients with deletions of the entire VHL gene. J Med Genet 2002;39:E38.
15. Hes F, Zewald R, Peeters T, et al. Genotype-phenotype correlations in families with deletions in the von Hippel-Lindau (VHL) gene. Hum Genet 2000;106:425-431.
16. Zhuang Z, Vortmeyer AO. Applications of tissue microdissection in cancer genetics. Cell Vis 1998;5:43-48.
17. Pinkel D, Gray JW, Trask B, et al. Cytogenetic analysis by in situ hybridization with fluorescently labeled nucleic acid probes. Cold Spring Harb Symp Quant Biol 1986;51:151-157.
18. Pack SD, Zbar B, Pak E, et al. Constitutional von Hippel-Lindau (VHL) gene deletions detected in VHL families by fluorescence in situ hybridization. Cancer Res 1999;59:5560-5564.
19. Vortmeyer AO, Huang SC, Pack SD, et al. Somatic point mutation of the wild-type allele detected in tumors of patients with VHL germline deletion. Oncogene 2002;21:1167-1170.
20. Gnarra JR, Ward JM, Porter FD, et al. Defective placental vasculogenesis causes embryonic lethality in VHL-deficient mice. Proc Natl Acad Sci USA 1997;94:9102-9107.
21. Chan CC, Koch CA, Kaiser-Kupfer MI, et al. Loss of heterozygosity for the NF2 gene in retinal and optic nerve lesions of patients with neurofibromatosis 2. J Pathol 2002;198:14-20.
22. Koch CA, Huang SC, Zhuang Z, et al. Somatic VHL gene deletion and point mutation in MEN 2A-associated pheochromocytoma. Oncogene 2002;21:479-482.
23. Wanebo JE, Lonser RR, Glenn GM, Oldfield EH. The natural history of hemangioblastomas of the central nervous system in patients with von Hippel-Lindau disease. J Neurosurg 2003;98:82-94.
24. Weil RJ, Lonser RR, DeVroom HL, et al. Surgical management of brainstem hemangioblastomas in patients with von Hippel-Lindau disease. J Neurosurg 2003;98:95-105.
25. Lonser RR, Weil RJ, Wanebo JE, et al. Surgical management of spinal cord hemangioblastomas in patients with von Hippel-Lindau disease. J Neurosurg 2003;98:106-116.
26. Lonser RR, Wait SD, Butman JA, et al. Surgical management of lumbosacral nerve root hemangioblastomas in von Hippel-Lindau disease. J Neurosurg 2003;99(suppl):64-69.
27. Maddock IR, Moran A, Maher ER, et al. A genetic register for von Hippel-Lindau disease. J Med Genet 1996;33:120-127.
28. Lamiell JM, Salazar FG, Hsia YE. von Hippel-Lindau disease affecting 43 members of a single kindred. Medicine 1989;68:1-29.
29. Hes F, Zewald R, Peeters T, et al. Genotype-phenotype correlations in families with deletions in the von Hippel-Lindau (VHL) gene. Hum Genet 2000;106:425-431.
30. Morrissey C, Martinez A, Zatyka M, et al. Epigenetic inactivation of the RASSF1A 3p21.3 tumor suppressor gene in both clear cell and papillary renal cell carcinoma. Cancer Res 2001;61:7277-7281.
31. Clifford SC, Prowse AH, Affara NA, et al. Inactivation of the von Hippel-Lindau (VHL) tumour suppressor gene and allelic losses at chromosome arm 3p in primary renal cell carcinoma: evidence for a VHL-independent pathway in clear cell renal tumourigenesis. Genes Chromosomes Cancer 1998;22:200-209.
32. Martinez A, Fullwood P, Kondo K, et al. Role of chromosome 3p12-p21 tumour suppressor genes in clear cell renal cell carcinoma: analysis of VHL dependent and VHL independent pathways of tumorigenesis. Mol Pathol 2000;53:137-144.
33. Haase VH, Glickman JN, Socolovsky M, Jaenisch R. Vascular tumors in livers with targeted inactivation of the von Hippel-Lindau tumor suppressor. Proc Natl Acad Sci USA 2001;98:1583-1588.